$SMMT
Summit Therapeutics Inc. Stock $smmt

$smmt Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000159929821000011 Filed on March 31, 2021

Income Statement

Concept	2020	2019 Q4	2019 Q1
Revenue	$860.0K	$120.0K	$510.0K
YoY Change	-98.49%	-82.35%	-84.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.23M	$4.370M	$3.020M
YoY Change	70.51%	-6.02%	-40.78%
% of Gross Profit
Research & Development	$53.27M	$7.220M	$9.540M
YoY Change	2.44%	-11.95%	-3.64%
% of Gross Profit
Depreciation & Amortization	$302.0K	$360.0K	$40.00K
YoY Change	-24.5%	0.0%	-73.33%
% of Gross Profit
Operating Expenses	$73.37M	$7.820M	$6.390M
YoY Change	-1.27%	-21.96%	-53.86%
Operating Profit	-$53.19M
YoY Change	-1087.07%
Interest Expense	$255.0K	-$60.00K	-$50.00K
YoY Change	-58.87%	0.0%	-89.8%
% of Operating Profit
Other Income/Expense, Net	$283.0K
YoY Change	-92.34%
Pretax Income	-$52.91M	-$7.760M	-$5.930M
YoY Change	-682.52%	-17.53%	-46.53%
Income Tax	-$213.0K	-$730.0K	-$770.0K
% Of Pretax Income
Net Earnings	-$52.70M	-$7.030M	-$5.160M
YoY Change	-584.84%	-13.53%	-54.26%
Net Earnings / Revenue	-6127.56%	-5858.33%	-1011.76%
Basic Earnings Per Share	-$0.76
Diluted Earnings Per Share	-$0.76	-$43.80K	-$50.61K
COMMON SHARES
Basic Shares Outstanding	69.52M shares
Diluted Shares Outstanding	69.52M shares

Balance Sheet

Concept	2020	2019 Q4	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$66.42M	$13.60M	$26.86M
YoY Change	4.03%	4.29%	33.63%
Cash & Equivalents	$66.42M	$63.84M	$35.25M
Short-Term Investments
Other Short-Term Assets	$11.07M	$1.399M	$1.903M
YoY Change	8.95%	-89.09%	-28.78%
Inventory
Prepaid Expenses		$8.762M	$9.681M
Receivables	$331.0K	$541.0K	$6.120M
Other Receivables	$9.856M	$3.670M	$6.330M
Total Short-Term Assets	$87.67M	$79.63M	$61.25M
YoY Change	10.1%	152.31%	20.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.279M	$518.0K	$649.0K
YoY Change	-16.89%	-17.78%	-31.9%
Goodwill		$1.961M	$1.951M
YoY Change			-44.46%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.82M	$16.62M	$18.32M
YoY Change	-10.81%	25.24%	-33.16%
TOTAL ASSETS
Total Short-Term Assets	$87.67M	$79.63M	$61.25M
Total Long-Term Assets	$14.82M	$16.62M	$18.32M
Total Assets	$102.5M	$96.25M	$79.57M
YoY Change	6.49%	114.7%	1.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.140M	$4.471M	$5.803M
YoY Change	37.33%	-15.8%	-7.26%
Accrued Expenses	$4.651M	$5.739M	$5.200M
YoY Change	-25.1%		-12.91%
Deferred Revenue		$2.615M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$360.0K	$360.0K
YoY Change
Total Short-Term Liabilities	$19.89M	$13.77M	$17.18M
YoY Change	44.48%	11.47%	-47.25%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$400.0K	$650.0K
YoY Change			-78.96%
Other Long-Term Liabilities	$3.155M	$2.703M	$2.429M
YoY Change	-12.8%	-1.35%	4.43%
Total Long-Term Liabilities	$3.155M	$2.703M	$2.429M
YoY Change	-12.8%	-1.35%	4.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.89M	$13.77M	$17.18M
Total Long-Term Liabilities	$3.155M	$2.703M	$2.429M
Total Liabilities	$23.05M	$17.39M	$23.75M
YoY Change	32.56%	3.54%	-71.27%
SHAREHOLDERS EQUITY
Retained Earnings		-$158.2M	-$130.9M
YoY Change			-7.03%
Common Stock		$672.0K	$321.0K
YoY Change			118.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$79.45M	$78.86M	$57.59M
YoY Change
Total Liabilities & Shareholders Equity	$102.5M	$96.25M	$79.57M
YoY Change	6.49%	114.7%	1.74%

Cashflow Statement

Concept	2020	2019 Q4	2019 Q1
OPERATING ACTIVITIES
Net Income	-$52.70M	-$7.030M	-$5.160M
YoY Change	-584.84%	-13.53%	-54.26%
Depreciation, Depletion And Amortization	$302.0K	$360.0K	$40.00K
YoY Change	-24.5%	0.0%	-73.33%
Cash From Operating Activities	-$48.11M	-$6.280M	-$4.660M
YoY Change	37.04%	46.05%	-19.52%
INVESTING ACTIVITIES
Capital Expenditures	$421.0K	-$10.00K	-$70.00K
YoY Change	168.15%		-12.5%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$190.0K
YoY Change			-96.01%
Cash From Investing Activities	-$421.0K	-$10.00K	-$250.0K
YoY Change	27.19%	0.0%	-94.83%
FINANCING ACTIVITIES
Cash Dividend Paid	$0.00
YoY Change
Common Stock Issuance & Retirement, Net	$50.00M
YoY Change	8.5%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$50.55M	-90.00K	19.44M
YoY Change	13.57%	12.5%
NET CHANGE
Cash From Operating Activities	-$48.11M	-6.280M	-4.660M
Cash From Investing Activities	-$421.0K	-10.00K	-250.0K
Cash From Financing Activities	$50.55M	-90.00K	19.44M
Net Change In Cash	$2.575M	-6.380M	14.53M
YoY Change	-61.85%	45.33%	-236.69%
FREE CASH FLOW
Cash From Operating Activities	-$48.11M	-$6.280M	-$4.660M
Capital Expenditures	$421.0K	-$10.00K	-$70.00K
Free Cash Flow	-$48.53M	-$6.270M	-$4.590M
YoY Change	37.63%	45.81%	-19.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001599298
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36866
CY2020	dei	Entity Registrant Name EntityRegistrantName	Summit Therapeutics Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	37-1979717
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	One Broadway, 14th Floor
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge,
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2020	dei	City Area Code CityAreaCode	617
CY2020	dei	Local Phone Number LocalPhoneNumber	514-7149
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020	dei	Trading Symbol TradingSymbol	SMMT
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1523000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4471000	USD
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	67000000.0	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82916189	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66417000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63842000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	331000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	541000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9547000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8762000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1399000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	9856000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	5084000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	87674000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	79628000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	725000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	518000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	554000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1021000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	2030000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	1961000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11515000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13120000	USD
CY2020Q4	us-gaap	Assets Assets	102498000	USD
CY2019Q4	us-gaap	Assets Assets	96248000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6140000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4261000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5739000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	729000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	366000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	471000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8370000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2615000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	105000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19890000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13767000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	569000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	493000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	422000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2511000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2703000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	23045000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	17385000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82575064	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82575064	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67178054	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67178054	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	826000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52003000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	672000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	293367000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241204000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3794000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4764000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210946000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158249000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	79453000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	78863000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102498000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96248000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	860000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	743000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57088000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53274000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39809000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19232000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11279000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17014000	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	859000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	5290000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	73365000	USD
	us-gaap	Operating Expenses OperatingExpenses	51088000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	74307000	USD
CY2020	us-gaap	Other Operating Income OtherOperatingIncome	19312000	USD
	us-gaap	Other Operating Income OtherOperatingIncome	22872000	USD
CY2019	us-gaap	Other Operating Income OtherOperatingIncome	22608000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-53193000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27473000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	5389000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	283000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1618000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3694000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52910000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29091000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9083000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-213000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1786000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-52697000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29127000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	10869000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.63
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69524148	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32829003	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17140494	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69524148	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32829003	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17228718	shares
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	970000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	51000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-496000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51727000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29076000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	10373000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-3589000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	133000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6295000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-496000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	10869000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	57589000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	845000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	51000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29127000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	78863000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	599000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1766000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	970000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-52697000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	79453000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-52697000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29127000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	10869000	USD
CY2020	smmt	Gain Loss On Remeasurement Of Liabilities Operating And Nonoperating GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating	480000	USD
	smmt	Gain Loss On Remeasurement Of Liabilities Operating And Nonoperating GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating	0	USD
CY2019	smmt	Gain Loss On Remeasurement Of Liabilities Operating And Nonoperating GainLossOnRemeasurementOfLiabilitiesOperatingAndNonoperating	4410000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-102000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-51000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1001000	USD
CY2020	smmt	Interest Expense Noncash InterestExpenseNoncash	255000	USD
	smmt	Interest Expense Noncash InterestExpenseNoncash	286000	USD
CY2019	smmt	Interest Expense Noncash InterestExpenseNoncash	615000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	278000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-423000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	451000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	347000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	443000	USD
CY2020	us-gaap	Depreciation Depreciation	302000	USD
	us-gaap	Depreciation Depreciation	321000	USD
CY2019	us-gaap	Depreciation Depreciation	409000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1250000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	970000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-13000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-55000	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	859000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	5290000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1766000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	845000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6295000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1906000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	58000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-212000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5439000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2467000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	447000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-952000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1260000	USD
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	24000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-492000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-580000	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	4381000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-3154000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2216000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5372000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2358000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-48973000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1642000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1306000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1296000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	144000	USD
CY2020	smmt	Increase Decrease In Business Combination Contingent Consideration Liability IncreaseDecreaseInBusinessCombinationContingentConsiderationLiability	0	USD
	smmt	Increase Decrease In Business Combination Contingent Consideration Liability IncreaseDecreaseInBusinessCombinationContingentConsiderationLiability	-703000	USD
CY2019	smmt	Increase Decrease In Business Combination Contingent Consideration Liability IncreaseDecreaseInBusinessCombinationContingentConsiderationLiability	0	USD
CY2020	smmt	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-459000	USD
	smmt	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-456000	USD
CY2019	smmt	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-430000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-235000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48111000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20757000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35106000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	0	USD
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	0	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	167000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	421000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	205000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	157000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	136000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-421000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-341000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-331000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50415000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46084000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	48000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	912000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1707000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	599000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	133000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50551000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49505000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44510000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	556000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2323000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2575000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28597000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6750000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63842000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35245000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28495000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66417000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63842000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35245000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-70000000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	63000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	72000	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Nature of the Business<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit Therapeutics Inc. ("Summit" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of novel antibiotics for serious infectious diseases. Summit is conducting a Phase 3 clinical program focused on the infectious disease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infection, or CDI. It is also seeking to expand the product candidate portfolio through the development of new mechanism, precision antibiotics using the proprietary Discuva Platform.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2020, Summit, a Delaware corporation, became the successor issuer to Summit Therapeutics plc, a public limited company incorporated under the laws of England and Wales with the Registrar of Companies of England and Wales, United Kingdom, for certain purposes under both the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such succession occurred pursuant to a statutory scheme of arrangement under U.K. law pursuant to which all Summit Therapeutics plc outstanding ordinary shares were exchanged on a five-for-one basis for newly issued shares of Summit common stock and Summit became the holding company of Summit Therapeutics plc (the predecessor registrant and former holding company) and its subsidiaries, which is referred to as the Redomiciliation Transaction. Concurrently, Summit Therapeutics plc was converted into a private limited company under the laws of England and Wales and renamed Summit Therapeutics Limited. In addition, the warrants and stock options to purchase shares of Summit Therapeutics plc were canceled and replacement warrants and stock options to purchase common stock in Summit Therapeutics Inc. were issued. The scheme of arrangement was accounted for as an exchange of equity interests among entities under common control. All assets and liabilities of Summit Therapeutics plc were assumed by Summit, resulting in the retention of the historical basis of accounting as if they had always been combined for accounting purposes and the historical consolidated financial statements of Summit Therapeutics plc became the historical consolidated financial statements of Summit Therapeutics Inc. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2020, there was a global outbreak of a novel coronavirus, or COVID-19, which was subsequently declared as a pandemic by the World Health Organization. The global impact of the outbreak rapidly evolved, triggering a period of global economic slowdown. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the estimates and assumptions underlying the consolidated financial statements are reasonable and supportable based on the information available as of December 31, 2020, however uncertainty over the ongoing impact COVID-19 will have on the global economy generally makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would be absent of the current and potential impacts of COVID-19. Actual results may ultimately differ from those estimates.</span></div>
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66400000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210900000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-52700000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48100000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Concentration of credit risk and of significant supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company's cash and cash equivalents are comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks and building societies. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and December 31, 2019 the majority of cash and cash equivalents were placed with HSBC Bank plc. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements, including with Eurofarma, BARDA and Carb-X. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div>
CY2020Q4	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	2	country
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	860000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	743000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57088000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	860000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	743000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57088000	USD
CY2020	smmt	Other Operating Income Remeasurement Of Financial Liabilities OtherOperatingIncomeRemeasurementOfFinancialLiabilities	0	USD
	smmt	Other Operating Income Remeasurement Of Financial Liabilities OtherOperatingIncomeRemeasurementOfFinancialLiabilities	0	USD
CY2019	smmt	Other Operating Income Remeasurement Of Financial Liabilities OtherOperatingIncomeRemeasurementOfFinancialLiabilities	715000	USD
CY2020	smmt	Research And Development Credit Tax Rebate ResearchAndDevelopmentCreditTaxRebate	9363000	USD
	smmt	Research And Development Credit Tax Rebate ResearchAndDevelopmentCreditTaxRebate	5473000	USD
CY2019	smmt	Research And Development Credit Tax Rebate ResearchAndDevelopmentCreditTaxRebate	2934000	USD
CY2020	smmt	Other Operating Income Other OtherOperatingIncomeOther	0	USD
	smmt	Other Operating Income Other OtherOperatingIncomeOther	0	USD
CY2019	smmt	Other Operating Income Other OtherOperatingIncomeOther	8000	USD
CY2020	us-gaap	Other Operating Income OtherOperatingIncome	19312000	USD
	us-gaap	Other Operating Income OtherOperatingIncome	22872000	USD
CY2019	us-gaap	Other Operating Income OtherOperatingIncome	22608000	USD
CY2020	smmt	Research And Development Credit Tax Rebate Small And Medium Enterprise ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise	9100000	USD
	smmt	Research And Development Credit Tax Rebate Small And Medium Enterprise ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise	4700000	USD
CY2019	smmt	Research And Development Credit Tax Rebate Small And Medium Enterprise ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise	2500000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	54000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1332000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	614000	USD
CY2020	smmt	Gain Loss On Remeasurement Of Liabilities Nonoperating GainLossOnRemeasurementOfLiabilitiesNonoperating	480000	USD
	smmt	Gain Loss On Remeasurement Of Liabilities Nonoperating GainLossOnRemeasurementOfLiabilitiesNonoperating	0	USD
CY2019	smmt	Gain Loss On Remeasurement Of Liabilities Nonoperating GainLossOnRemeasurementOfLiabilitiesNonoperating	3695000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2020	us-gaap	Interest Expense InterestExpense	255000	USD
	us-gaap	Interest Expense InterestExpense	291000	USD
CY2019	us-gaap	Interest Expense InterestExpense	620000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	283000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1618000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3694000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-51197000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-29224000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	7549000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1713000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	133000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1534000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52910000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29091000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9083000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-213000	USD
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	36000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	120000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-213000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	36000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	120000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1906000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1906000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-213000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1786000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	29831000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20095000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1167000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	319000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	491000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	34000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31489000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20448000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2189000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2057000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	71000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2260000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2057000	USD
CY2020Q4	smmt	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	29229000	USD
CY2019Q4	smmt	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	18391000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29229000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18391000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29200000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8800000	USD
	smmt	Valuation Allowance Deferred Tax Asset Increase Decrease Due To Change In Enacted Tax Rate Amount ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount	2300000	USD
	smmt	Deferred Tax Assets Net Increase Decrease Due To Change In Enacted Tax Rate Amount DeferredTaxAssetsNetIncreaseDecreaseDueToChangeInEnactedTaxRateAmount	2300000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.121
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.112
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.165
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.039
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.012
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.264
CY2020	smmt	Effective Income Tax Rate Reconciliation Tax Credit Refundable Research Percent EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent	0.070
	smmt	Effective Income Tax Rate Reconciliation Tax Credit Refundable Research Percent EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent	0.065
CY2019	smmt	Effective Income Tax Rate Reconciliation Tax Credit Refundable Research Percent EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent	0.238
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.009
CY2020Q4	us-gaap	Goodwill Goodwill	2030000	USD
	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.047
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.028
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.014
	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2020	smmt	Effective Income Tax Rate Reconciliation Release Of Temporary Differences For Intangible Assets Percent EffectiveIncomeTaxRateReconciliationReleaseOfTemporaryDifferencesForIntangibleAssetsPercent	0
	smmt	Effective Income Tax Rate Reconciliation Release Of Temporary Differences For Intangible Assets Percent EffectiveIncomeTaxRateReconciliationReleaseOfTemporaryDifferencesForIntangibleAssetsPercent	0
CY2019	smmt	Effective Income Tax Rate Reconciliation Release Of Temporary Differences For Intangible Assets Percent EffectiveIncomeTaxRateReconciliationReleaseOfTemporaryDifferencesForIntangibleAssetsPercent	-0.209
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.003
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.197
CY2020	smmt	Research And Development Credit Tax Rebate Small And Medium Enterprise ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise	9100000	USD
	smmt	Research And Development Credit Tax Rebate Small And Medium Enterprise ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise	4700000	USD
CY2019	smmt	Research And Development Credit Tax Rebate Small And Medium Enterprise ResearchAndDevelopmentCreditTaxRebateSmallAndMediumEnterprise	2500000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-52697000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29127000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	10869000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69524000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32829000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17140000	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	89000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69524000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32829000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17229000	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	10000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1000000.0	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.63
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9521000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13403000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1715000	shares
CY2019Q4	us-gaap	Goodwill Goodwill	1961000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	1951000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	69000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	1961000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	900000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20170000	USD
CY2020Q4	smmt	Finite Lived Intangible Assets Accumulated Amortization And Impairment FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment	8655000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11515000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19762000	USD
CY2019Q4	smmt	Finite Lived Intangible Assets Accumulated Amortization And Impairment FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment	6642000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13120000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000.0	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1000000.0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1000000.0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000000.0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1000000.0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1000000.0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1000000.0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000000.0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1000000.0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1000000.0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1854000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1542000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1129000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1024000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	725000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	518000	USD
CY2020	us-gaap	Depreciation Depreciation	300000	USD
	us-gaap	Depreciation Depreciation	300000	USD
CY2019	us-gaap	Depreciation Depreciation	400000	USD
CY2020Q4	smmt	Research And Development Prepaid Expenses Current ResearchAndDevelopmentPrepaidExpensesCurrent	8500000	USD
CY2019Q4	smmt	Research And Development Prepaid Expenses Current ResearchAndDevelopmentPrepaidExpensesCurrent	7700000	USD
CY2020Q4	smmt	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1500000	USD
CY2019Q4	smmt	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3200000	USD
CY2020	smmt	Research And Development Prepaid Expenses Effect Of Five Percentage Point Increase ResearchAndDevelopmentPrepaidExpensesEffectOfFivePercentagePointIncrease	1900000	USD
CY2020	smmt	Research And Development Prepaid Expenses Effect Of Five Percentage Point Decrease ResearchAndDevelopmentPrepaidExpensesEffectOfFivePercentagePointDecrease	2300000	USD
CY2019Q4	smmt	Financial Liability On Funding Arrangement Noncurrent FinancialLiabilityOnFundingArrangementNoncurrent	0	USD
CY2020Q4	smmt	Financial Liability On Funding Arrangement Noncurrent FinancialLiabilityOnFundingArrangementNoncurrent	0	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	USD
	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	700000	USD
CY2020	smmt	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	2	contract
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	600000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1000000.0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	401000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	76000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	477000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	465000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	465000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0375
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0375
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	478000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	447000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	501000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	488000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	435000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	369000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8620082	shares
CY2020Q4	smmt	Business Combination Assumed Contingent Liability Noncurrent BusinessCombinationAssumedContingentLiabilityNoncurrent	2300000	USD
CY2019Q4	smmt	Business Combination Assumed Contingent Liability Noncurrent BusinessCombinationAssumedContingentLiabilityNoncurrent	2400000	USD
CY2020Q4	smmt	Business Combination Assumed Contingent Liability Noncurrent BusinessCombinationAssumedContingentLiabilityNoncurrent	2300000	USD
CY2020Q4	smmt	Business Combination Assumed Contingent Liability Discount Rate One Percentage Point Decrease BusinessCombinationAssumedContingentLiabilityDiscountRateOnePercentagePointDecrease	2416000	USD
CY2020Q4	smmt	Business Combination Assumed Contingent Liability Discount Rate One Percentage Point Increase BusinessCombinationAssumedContingentLiabilityDiscountRateOnePercentagePointIncrease	2129000	USD
CY2020Q4	smmt	Business Combination Assumed Contingent Liability Probability Of Success Ten Percentage Point Decrease BusinessCombinationAssumedContingentLiabilityProbabilityOfSuccessTenPercentagePointDecrease	1864000	USD
CY2020Q4	smmt	Business Combination Assumed Contingent Liability Probability Of Success Ten Percentage Point Increase BusinessCombinationAssumedContingentLiabilityProbabilityOfSuccessTenPercentagePointIncrease	2630000	USD
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	335900000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67200000	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5821137	shares
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
CY2019	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
CY2020Q4	smmt	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStock	0.04
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4644835	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.80
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3135204	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.47
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3791662	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.07
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	315409	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.88
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3672968	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.90
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6641000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3488858	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.89
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y10M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6325000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	769564	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.36
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1817000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.20
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.65
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.00
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	900000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1434410	shares
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3800000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y7M6D
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3358732	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.44
CY2019Q4	smmt	Class Of Warrant Or Right Quarterly Vesting Period ClassOfWarrantOrRightQuarterlyVestingPeriod	P3Y
CY2019Q4	smmt	Class Of Warrant Or Right Quarterly Vesting Period ClassOfWarrantOrRightQuarterlyVestingPeriod	P3Y
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1766000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	845000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6295000	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	0	USD
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01

Files In Submission

Name	View Source	Status
0001599298-21-000011-index-headers.html	Edgar Link	pending
0001599298-21-000011-index.html	Edgar Link	pending
0001599298-21-000011.txt	Edgar Link	pending
0001599298-21-000011-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smmt-20201231.htm	Edgar Link	pending
smmt-20201231.xsd	Edgar Link	pending
smmt-20201231_cal.xml	Edgar Link	unprocessable
smmt-20201231_def.xml	Edgar Link	unprocessable
smmt-20201231_g1.jpg	Edgar Link	pending
smmt-20201231_g2.jpg	Edgar Link	pending
smmt-20201231_g3.jpg	Edgar Link	pending
smmt-20201231_g4.jpg	Edgar Link	pending
smmt-20201231_g5.jpg	Edgar Link	pending
smmt-20201231_g6.jpg	Edgar Link	pending
smmt-20201231_htm.xml	Edgar Link	completed
smmt-20201231_lab.xml	Edgar Link	unprocessable
smmt-20201231_pre.xml	Edgar Link	unprocessable
sum-ex1035_20201231x10k.htm	Edgar Link	pending
sum-ex1036_20201231x10k.htm	Edgar Link	pending
sum-ex211_20201231x10k.htm	Edgar Link	pending
sum-ex231_20201231x10k.htm	Edgar Link	pending
sum-ex311_20201231x10k.htm	Edgar Link	pending
sum-ex312_20201231x10k.htm	Edgar Link	pending
sum-ex321_20201231x10k.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMMT
Summit Therapeutics Inc. Stock $smmt

2020 Form 10-K Financial Statement

#000159929821000011 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT Summit Therapeutics Inc. Stock $smmt

2020 Form 10-K Financial Statement

#000159929821000011 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT
Summit Therapeutics Inc. Stock $smmt